Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, discusses the JAVELIN BLADDER 100 trial, a study comparing avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC). Dr. Petros focuses on the association between clinical outcomes and exploratory biomarkers. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
